This week, four pharmaceutical stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
Johnson & Johnson (JNJ) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum and Equity, JNJ also gets A’s. The stock’s dividend yield is 2.6%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.
Bristol-Myers Squibb Company (BMY) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of BMY stock.
This is a strong week for Watson Pharmaceuticals (WPI). The company’s rating climbs to A from the previous week’s B. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
This week, Repros Therapeutics (RPRX) pushes up from a B to an A rating. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.